The Von Hippel-Lindau Disease Market report provides current treatment practices, emerging drugs, Von Hippel-Lindau (VHL) Disease market share of the individual therapies, current and forecasted Von Hippel-Lindau (VHL) Disease market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Von Hippel-Lindau (VHL) Disease diagnostic criteria, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Von Hippel-Lindau Disease Overview
Von Hippel–Lindau (VHL) disease is an autosomal dominantly inherited disorder that demonstrates marked phenotypic variability and age-dependent penetrance. A germline mutation in the VHL gene predisposes carriers to the development of abundantly vascularized tumors in multiple organs.
Request free sample copy- https://www.delveinsight.com/sample-request/von-hippel-lindau-disease-market
List of regions covered in the report-
List of companies involved in the report-
Von Hippel-Lindau Disease Symptoms
The most common symptom of VHL is hemangioblastomas. CNS hemangioblastomas are among the most common manifestations of VHL disease. Other than this, VHL clinical manifestations also include, Renal Cell Carcinomas (RCC), Renal Cysts, Pheochromocytoma, Retinal hemangioblastomas, Papillary cystadenomas of the broad ligament, Cystadenomasin the epididymis, Pancreatic Neuroendocrine Tumors and Cysts, and Endolymphatic sac tumors (ELSTs).
Von Hippel-Lindau Disease Diagnosis
Diagnostic tests include, initial screening workup including a thorough history and clinical examination, an ophthalmologic examination including fundoscopy, MR imaging of the craniospinal axis, kidneys, pancreas, and liver, an audiological examination, and laboratory tests (to detect pheochromocytomas). Genetic testing of the peripheral leukocytes and/or other body tissues is performed to confirm the presence of a VHL gene mutation.
Von Hippel-Lindau Disease Treatment Market
Treatment for VHL disease depends on the location and size of tumors. In general, the goal is to treat growths when they cause symptoms but are still small, so they do not cause permanent damage. Although there is no cure for VHL, the associated tumors can be treated. Treatment usually involves surgical removal of tumors. Radiation therapy may be used in some cases. Early detection and treatment of tumors significantly improve a patient’s diagnosis. Systemic treatment is recommended in the metastatic setting, addressing the same therapeutic principles as in sporadic malignancies. Due to the rarity of VHL, data on systemic treatment is sparse. VEGF-targeting agents seem to be a reasonable choice with regard to pathophysiology in most tumors.
Von Hippel-Lindau Disease Market Insights
VHL disease is caused by a flaw in one gene, the VHL gene, which regulates cell growth. This flaw, for which the cause is unknown, leads to the abnormal growth of blood vessels in certain parts of the body. Instead of growing and spreading out normally (like a tree), in patients with VHL, the blood vessels grow into clumps.
Von Hippel-Lindau Disease Emerging Drugs
Von Hippel-Lindau Disease Market Report Highlights
Table of Content
1. Key Insights
2. Report Introduction
3. Von Hippel-Lindau (VHL) disease Market Overview at a Glance
4. Executive Summary of Von Hippel-Lindau (VHL) disease
5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Diagnosis of VHL
8. Diagnostic Guidelines
9. Current Treatment Practices of VHL
10. Treatment Guidelines
11. Epidemiology and Patient Population
12. Patient Journey
13. Key Endpoints in Von Hippel–Lindau (VHL) Disease Clinical Trials
14. Emerging Therapies
15. Von Hippel–Lindau Disease: 7 Major Market Analysis
16. Market Access and Reimbursement
17. KOL Views
18. Market Drivers
19. Market Barriers
20. SWOT Analysis
21. Unmet Needs
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
Von Hippel–Lindau Market Report Scope
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/